A review of 6 placebo-managed medical trials with 1,134 complete members concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) have been connected to a greater regular advancement around the Ashworth scale for spasticity in various sclerosis clients in comparison with placebo, Though